Tamtam Try Tamtam free
Bayer logo

Bayer account plan

Global, Health, Nutrition, Science

At a glance

Bayer is a German life science group in crop science, pharmaceuticals and consumer health, with 2025 sales of €45,575 million and 88,078 employees.

Bayer, headquartered in Leverkusen, is a life science group with three divisions: Crop Science (seeds, traits, crop protection and digital farming), Pharmaceuticals (prescription medicines and radiology) and Consumer Health (nonprescription self-care brands). It had 272 consolidated companies in approximately 80 countries and 88,078 employees (FTE) at Dec. 31, 2025. FY2025 sales were €45,575 million, EBITDA before special items €9,669 million (margin 21.2%) and core EPS €4.91, while net income was minus €3,620 million after litigation charges. Bayer AG is listed and run by CEO Bill Anderson, whose contract runs to March 31, 2029.

Business units

Strategic priorities

Five turnaround priorities
The CEO lists pharma pipeline, Crop Science profitability, debt, litigation and bureaucracy as "no-regret moves" whether Bayer stays together or does something different with a division.
Contain glyphosate litigation
A proposed US class settlement of up to US$7.25 billion over up to 21 years and the June 2026 Supreme Court Durnell ruling on FIFRA preemption aim to significantly contain litigation by the end of 2026.
Crop Science Five-Year Framework
Return to mid-20% EBITDA margins and launch ten blockbusters with sales over €500 million each within ten years, with new value pools in biologicals, hybrid wheat and biofuels.
Pharma growth drivers
Launch Nubeqa, Kerendia, Beyonttra, Lynkuet and asundexian, which is being readied for market in Q4 2026, and grow the US business.
Dynamic Shared Ownership and AI
Up to six organizational layers removed, management cut by roughly two-thirds and 90-day cycles; agentic AI is the next lever for effectiveness.
Debt reduction
The new CFO's priorities are to strengthen the balance sheet and improve productivity and cash generation; net financial debt guidance for 2026 is €29.0 to €30.0 billion.

Latest results

In H1 2026 sales were €24,277 million, +3.3% currency and portfolio adjusted, and EBITDA before special items rose 6.6% to €6,597 million (margin 27.2%), with core EPS of €3.66. Crop Science led, with EBITDA before special items up 20.5% to €3,916 million, while Pharmaceuticals was flat as Xarelto (–41.4%) and Eylea (–26.8%) fell. Free cash flow was minus €2,691 million due to litigation payouts, and net financial debt reached €33,647 million at June 30, 2026. The 2026 guidance was confirmed: currency-adjusted sales €45 to €47 billion, EBITDA before special items €9.6 to €10.1 billion and core EPS €4.30 to €4.80.

Investments and deals

Apollo minority investment
In July 2026 Apollo-managed funds agreed a €3.0 billion minority investment in a new entity holding the long-acting reversible contraceptives business; Bayer keeps control.
Capital expenditure
Capex was €2,487 million in 2025, including R&D expansion in Monheim, fungicide capacity in Dormagen, cell and gene therapy facilities and a new Consumer Health site in Qidong, China.
Pharma deals
Acquisition of Perfuse Therapeutics (upfront about €260 million) for a glaucoma and diabetic retinopathy implant, cardiac amyloidosis radiotracers, and an AI drug discovery collaboration with Iambic.
Crop Science partnerships
An alliance with bp on camelina for biofuels and an exclusive hybrid wheat licence with RAGT, expected to bring annual revenues of up to €1 billion by the mid-2040s.
Divestments and Ruveon
Avelox was sold for €250 million and the US glyphosate business was consolidated into Ruveon LLC.

Challenges and risks

Litigation payouts
About €5 billion of litigation payouts are expected in 2026, driving free cash flow guidance of minus €2.5 to minus €1.5 billion; PCB cases continue.
Loss of exclusivity
Xarelto and Eylea active-ingredient protection has expired in key markets, with Xarelto down 31.6% in 2025.
Crop protection pressure
Generic price pressure, possible restrictions on crop protection actives and the dicamba label vacatur weighed on Crop Science.
Pharmaceutical pricing
Stricter US pricing actions, including most-favoured-nation pricing, and China's volume-based procurement are rated risks.
Credit ratings
Ratings are BBB / Baa2 / BBB; Moody's moved to stable in July 2026 while S&P and Fitch remain negative.

What leadership says

“If dynamic shared ownership is our opportunity to make the enterprise more entrepreneurial, agentic artificial intelligence is our chance to make the organization more effective”

Bill Anderson, CEO · Annual Stockholders' Meeting address, April 24, 2026

“We're definitely in a better position now than we've been at any point in the last few years to make strategic choices”

Bill Anderson, CEO · Q2 2026 earnings call, August 4, 2026

“To continue to strengthen the balance sheet, to improve productivity and cash generation, and to create flexibility to invest for future growth.”

Judith Hartmann, CFO · Q2 2026 earnings call, August 4, 2026

“We're not going to do major acquisitions.”

Stefan Oelrich, Head of Pharmaceuticals · Q2 2026 earnings call, August 4, 2026

Where a supplier can help

Agentic AI and IT infrastructure
Tied to the Dynamic Shared Ownership and AI priority: Bayer is investing in IT infrastructure and data for agentic AI.
Productivity and cost tools
Tied to the debt reduction priority and the Crop Science Five-Year Framework: offers that lower cost of goods and overhead.
Launch commercial support
Tied to the pharma growth drivers: market access, medical affairs and launch services for asundexian, Lynkuet and Kerendia.
Agricultural innovation partners
Tied to Crop Science partnerships: biologicals, hybrid wheat, biofuels and digital farming collaborations.
Regulatory and legal operations
Tied to the litigation challenge: claims administration, regulatory science and legal operations support.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Bayer?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Bayer

What does Bayer do?

Bayer is a life science company with three divisions: Crop Science (seeds, traits and crop protection), Pharmaceuticals (prescription medicines and radiology) and Consumer Health (nonprescription self-care products).

What is Bayer's revenue?

Bayer's sales were €45,575 million in 2025; for 2026 it guides currency-adjusted sales of €45 to €47 billion.

How many employees does Bayer have?

Bayer had 88,078 employees (FTE) at Dec. 31, 2025 and 87,830 at June 30, 2026.

Who leads Bayer?

Bill Anderson is CEO (Chairman of the Board of Management); Judith Hartmann has been CFO since June 1, 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)